TCT-62 Five-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Scaffolds: Results From the Randomized ABSORB II Trial — Patrick W. Serruys (2018) | RDL Network
Yoshinobu Onuma, Bernard Chevalier, Masafumi Ono, Ángel Cequier, Dariusz Dudek, Michael Haude, Didier Carrié, Manel Sabaté, Stephan Windecker, Richard Rapoza, Nick E.J. West, Sebastian Reith, Manuel de Sousa Almeida, Gianluca Campo, Andrés Íñiguez, Patrick W. Serruys
Takashi Muramatsu, Yoshinobu Onuma, Robert J. Van Geuns, Bernard Chevalier, Tejas Patel, Ashok Seth, Roberto Diletti, Héctor M. García‐García, Cécile Dorange, Susan Veldhof, Wai‐Fung Cheong, Robert Whitbourn, Antonio L. Bartorelli, Alexandre Abizaid, Patrick W. Serruys
Dean J. Kereiakes, Stephen G. Ellis, Runlin Gao, Takeshi Kimura, Yoshinobu Onuma, Karine Piard‐Ruster, Yunlong Zhang, Kai Koo, Patrick W. Serruys, Gregg W. Stone
Yuki Katagiri, Patrick W. Serruys, Carlos Macaya, John A. Ormiston, Jonathan Hill, Iréne Lang, Mohaned Egred, Jean Fajadet, Maciej Lesiak, Joanna J. Wykrzykowska, Jan J. Piek, Manel Sabaté, Stephan Windecker, Bernard Chevalier, Yoshinobu Onuma
Discussion(0)
No comments yet. Be the first to comment.